# **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C08F 8/48, C07D 413/12		(11) International Publication Number: WO 94/18247
		(43) International Publication Date: 18 August 1994 (18.08.94)
(21) International Application Number: PCT/US		KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SE,
(22) International Filing Date: 1 February 1994 (	01.02.9	SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 08/012,447 2 February 1993 (02.02.93)	τ	S Published With international search report. With amended claims and statement.
(71) Applicant: ENZON, INC. [US/US]; 40 Kingsbrid Piscataway, NJ 08854 (US).	ge Roa	
(72) Inventor: GREENWALD, Richard, B.; 113 Hickon Somerset, NJ 08873 (US).	ory Roa	
(74) Agents: MERCANTI, Michael, N. et al.; Enzon, Kingsbridge Road, Piscataway, NJ 08854 (US).	Inc.,	0
(54) Title: AZLACTONE ACTIVATED POLYALKYLE	NE OX	DES

#### (54) Title: AZLACTONE ACTIVATED POLYALKYLENE OXIDES

## (57) Abstract

Water-soluble azlactone activated polyalkylene oxides having improved hydrolytic stability and conjugates of the azlactone activated polyalkylene oxides with biologically active nucleophiles are disclosed. Methods of forming and conjugating the activated polyalkylene oxides with biologically active nucleophiles are also disclosed.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
ΑÜ	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	rr	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gahon		-		

WO 94/18247 PCT/US94/01139

# AZLACTONE ACTIVATED POLYALKYLENE OXIDES

## 5 BACKGROUND OF THE INVENTION

10

15

20

25

30

35

The present invention relates to azlactone activated polyalkylene oxides (PAO's) having improved hydrolytic stability, and to water-soluble polyalkylene oxide conjugates prepared therefrom.

The conjugation of water-soluble polyalkylene oxides with useful molecules such as proteins and polypeptides is well known. The coupling of peptides and polypeptides to polyethylene glycol (PEG) and similar water-soluble polyalkylene oxides is disclosed by U.S. Patent No. 4,179,337 to Davis et al.

Davis et al. discloses that physiologically active polypeptides modified with PEG exhibit dramatically reduced immunogenicity and antigenicity. Also, the polyalkylene oxide conjugates, when injected into a living organism, have been shown to remain in the bloodstream considerably longer than the corresponding native proteins. Examples of such therapeutic protein conjugates include tissue plasminogen activator, insulin, interleukin II and hemoglobin. In addition, PAO's have also been conjugated to oligonucleotides. See, for example, U.S. Patent No. 4,904,582.

To conjugate polyalkylene oxides, the hydroxyl end-groups of the polymer must first be converted into reactive functional groups. This process is frequently referred to as "activation" and the product is called an "activated polyalkylene oxide."

Until recently, covalent attachment of the polyalkylene oxide to an appropriate nucleophile was effected by activated polyalkylene oxides such as polyalkylene oxide succinoyl-N-hydroxysuccinimide ester, as disclosed by Abuchowski et al., <u>Cancer Biochem.</u>

10

15

20

25


30

<u>Biophys.</u>, 7, 175-86 (1984). This polyalkylene oxide derivative is desirable because it is reactive under mild conditions.

A shortcoming associated with this derivative, however, is the fact that it is relatively hydrolytically unstable when no nucleophile is present. Recently, in U.S. Patent No. 5,122,614, polyalkylene oxide-N-succinimide carbonates were disclosed having improved hydrolytic stability over the polyalkylene oxide succinoyl succinates. Even so, the pH conditions necessary to deprotonate the  $\epsilon$ -NH, groups of polypeptide for conjugation subject the activated lysines polyalkylene oxide to hydrolysis. This does not affect the reaction end product, other than to reduce its yield. While reduced yields ordinarily affect product cost, the hydrolysis becomes even more costly for several reasons. reaction mixtures cannot be significantly in advance. Additional purification of the end product is required to remove the hydrolytic Furthermore, the reduction in degradation products. yield is compensated for by increasing the amount of activated polyalkylene oxide starting material. increases the viscosity of the reaction mixture, thereby further increasing the processing cost, and potentially interferes with downstream purification of the polymer and conjugate.

A need exists, therefore, for polyalkylene oxides that are unreactive towards weak nucleophiles such as water but react readily with stronger nucleophiles such as polypeptides. While azlactones have been reported to react readily with amines and less readily with water, azlactone activated PAO's are unreported. Unsaturated azlactones, in particular, are not altered by long contact with water. See, Carter, Organic Reactions,

Vol. III (Adams, ed., John Wiley & Sons, New York 1946) pp. 198-239. The disclosed unsaturated azlactones have the following structures:



in which  $R_1$  and  $R_2$  are independently selected from hydrogen, phenyl rings and lower alkyl moieties. R is the residue of an a-acyl amino acid.

15

20

25

#### SUMMARY OF THE INVENTION

It has now been discovered that certain azlactone substituted polyalkylene oxides possess a desirable combination of nucleophilic reactivity and hydrolytic stability. For the conjugation of polyalkylene oxides with bioactive materials, the desired aminolysis predominates over hydrolysis, so that reactions in aqueous solutions occur with higher yields. The azlactone activated polyalkylene oxides have improved resistance to hydroxyl attack under the pH conditions which are required in order to deprotonate the protein amines.

SUBSTITUTE SHEET (RULE 26)

The water-soluble azlactone activated polyalkylene oxides of the present invention include unsaturated azlactone activated polyalkylene oxides, represented by the structure of Formula IA:

X-R-L (IA)

10

15

20


5

wherein L is selected from -O-,  $-\text{CH}_2-$  and amino acid and polypeptide residues;

R is a water-soluble polyalkylene oxide;

 $R_{\rm I}$  is a moiety selected from hydrogen, alkyl and cycloalkyl moieties, carbocyclic and heterocyclic aromatic rings, and  $\alpha,\beta$ -unsaturated alkyl moieties; and X is a terminal moiety of the polyalkylene oxide.

The water-soluble azlactone activated polyalkylene oxides of the present invention also include saturated azlactone activated polyalkylene oxides, represented by the structure of Formula IB:



30

wherein L, R and X are the same as described above with respect to Formula IA and  $R_4$  and  $R_5$  are moieties independently selected from hydrogen, alkyl, aryl and alkylaryl moieties. The saturated azlactone activated polyalkylene oxides having the structure of Formula IB in

10

15

20

which  $R_4$  and  $R_5$  are both hydrogen do not have significantly improved hydrolytic stability, but are useful intermediates in the preparation of the unsaturated azlactone activated polyalkylene oxides of Formula IA.

Therefore, in accordance with the present invention, water-soluble azlactone activated polyalkylene oxides are provided. The azlactone activated polyalkylene oxides of the present invention include the unsaturated azlactones of Formula IA and the saturated azlactones of Formula IB. The saturated azlactones of Formula IB include species in which both of  $R_1$  and  $R_2$  are hydrogen.

One process for forming the unsaturated azlactone-activated polyalkylene oxides of Formula IA reacts an a-acyl amino acid terminated polyalkylene oxide with an aromatic or unsaturated aliphatic aldehyde in the presence of acetic anhydride. Therefore, in accordance with the present invention there is provided a process for the preparation of water-soluble unsaturated azlactone activated polyalkylene oxides, which process includes the steps of:

providing an  $\alpha$ -acyl amino acid terminated polyalkylene oxide having a structure corresponding to Formula II:

 $X-R-L-CO-NH-CH_2-COOH \qquad (II)$ 

and reacting the amino acid terminated polyalkylene oxide with acetic anhydride and an aldehyde having a structure corresponding to Formula III:

 $R_1$ -C=O (III)

so that an unsaturated azlactone activated polyalkylene oxide is formed having a structure corresponding to Formula IA, in which R, L and X are the same as described above with respect to Formula IA. For this process, R<sub>1</sub> is selected from carbocyclic and heterocyclic aromatic

15

20

30

6

rings and  $\alpha, \beta$ -unsaturated alkyl moieties.

acid terminated the amino Alternatively, v polyalkylene oxide of Formula II may first be reacted with acetic anhydride to form the saturated azlactone substituted polyalkylene oxide of Formula IB in which both  $R_4$  and  $R_5$  are hydrogen. The saturated azlactone may be recovered at this point as a useful intermediate in the preparation of the unsaturated azlactones Formula IA, or it may be further reacted with the aldehyde of Formula III to form the unsaturated azlactone activated polyalkylene oxide of Formula IA in which R1 is selected from carbocyclic and heterocyclic aromatic rings and  $\alpha$ ,  $\beta$ -unsaturated alkyl moieties.

The unsaturated azlactone activated polyalkylene oxides of Formula IA may also be formed by the reaction of an  $\alpha$ -acyl- $\beta$ -hydroxy, alkoxy or alkyl ester amino acid terminated polyalkylene oxide with acetic anhydride. Therefore, in accordance with the present invention there is provided still another process for the preparation of water-soluble unsaturated azlactone activated polyalkylene oxides, which process includes the steps of:

providing an  $\alpha$ -acyl amino acid terminated polyalkylene oxide having a structure corresponding to Formula IIA:

and reacting the amino acid terminated polyalkylene oxide with acetic anhydride so that an azlactone activated polyalkylene oxide is formed having a structure corresponding to Formula IA, wherein R,  $R_1$ , L and X are the same as described above with respect to Formula IA.  $R_6$  is a moiety selected from hydroxyl, alkoxy and alkylester moieties.

The saturated azlactone activated polyalkylene

10

15

20

25

30

7

oxides of Formula IB in general are formed by reacting a  $\alpha$ -acyl amino acid terminated polyalkylene oxide with acetic anhydride. Therefore, in accordance with the present invention there is provided a process for the preparation of water-soluble saturated azlactone activated polyalkylene oxides, which process includes the steps of:

providing an  $\alpha$ -acyl amino acid terminated polyalkylene oxide having a structure corresponding to Formula IIB:

$$X-R-L-CO-NH-C-COOH$$
 (IIB)

and reacting the amino acid terminated polyalkylene oxide with acetic anhydride so that a saturated azlactone activated polyalkylene oxide is formed having a structure corresponding to Formula IB in which R, L and X are the same as described above with respect to Formula IA and  $R_4$  and  $R_5$  are moieties independently selected from hydrogen, alkyl, aryl and alkylaryl moieties.

The azlactone activated polyalkylene oxides of the present invention react with biologically active nucleophiles to form covalently bonded conjugates thereof. When the biologically active nucleophile is a protein or polypeptide, conjugation occurs at the  $e-NH_2$  moieties of lysines.

The present invention therefore also provides a method of forming a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded thereto, which method includes the steps of:

contacting a biologically active nucleophile with an azlactone activated polyalkylene oxide, so that a biologically active conjugate of the biologically

10

15

20

25

30

active nucleophile and the polyalkylene oxide is formed; and recovering the biologically active conjugate.

The present invention therefore also includes a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded thereto by a linkage formed by reacting the nucleophile with an azlactone activated polyalkylene oxide.

The biologically active conjugates of the present invention possess numerous therapeutic applications. Therefore, there is also included in the present invention a method of treatment in which a mammal in need thereof is administered a therapeutically effective amount of the biologically active conjugates of the present invention.

The hydrolytic stability of the azlactone activated polyalkylene oxides of the present invention permit bulk solutions of activated polyalkylene oxide to be prepared in advance of production runs. Furthermore, the azlactone group can be reacted with a variety of biologically active nucleophiles of interest other than lysine e-amino groups of polypeptides. For example, the azlactone activated polyalkylene oxides of the present invention will react with any primary or secondary amino The azlactones will also react with other group. nucleophilic peptide groups, such as α-amino groups, guanidino moieties, mercapto groups, and the like, at the In addition, the azlactones are also appropriate pH. reactive with nucleotides such as guanine, adenine, and like, and derivatives thereof which possess the nucleophilic amino groups.

15

20

25

30

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The azlactone activated polyalkylene oxides of the preferably prepared present invention are polyalkylene oxides that are soluble in water at room Polyalkylene oxides meeting temperature. requirement are polyethylene glycol (PEG) and copolymers Block copolymers of PEG with polypropylene thereof. glycol or polypropylene oxide are also suitable for use with the present invention, provided that the degree of block copolymerization is not so great as to render the polymer insoluble in water at room temperature. Other polymers suitable for use with the present invention include polyacrylates, polymethacrylates and polyvinyl alcohols.

The molecular weight of the polyalkylene oxide will depend mainly upon the end use of a particular polymer conjugate. Those of ordinary skill in the art are capable of determining molecular weight ranges suitable for their end-use applications. In general, the useful range of molecular weight is a number average molecular weight between about 600 and about 100,000 daltons, and preferably between about 2,000 and about 20,000 daltons. A molecular weight of 5,000 daltons is most preferred.

Preferred azlactone activated polyalkylene oxides are represented by the structures of Formula IA and IB, wherein R is a water-soluble polyalkylene oxide, L is selected from -O-,  $-CH_2-$ , amino acid and peptide residues;  $R_1$  is a moiety selected from hydrogen, alkyl, phenyl, phenylalkyl and cycloalkyl moieties, and X is a terminal moiety of the polyalkylene oxide.

X can be a group into which a terminal hydroxyl group may be converted, including the reactive derivatives of the prior art disclosed in U.S. Patent Nos. 4,179,337, 4,847,325, 5,122,614 and in copending and

10

15

20

25

30

commonly owned U.S. Patent Application Serial No. 626,696, filed March 18, 1991, the disclosures of all of which are hereby incorporated herein by reference thereto. The heterobifunctional polymers can be prepared by methods known to those skilled in the art without undue experimentation. When the moieties selected for L and  $R_1$  on both ends of the polymer are identical, the polymer will then be a symmetrical, homobifunctional polymer derivative.

Such double polymer substitution can result in either intra- or intermolecular crosslinking of the nucleophile, which, in some cases, can be useful. Such crosslinking can be controlled by the amount of polymer used and the concentration of reacting species, which methods are well-known to those of ordinary skill in the art.

Crosslinking can also be prevented by using a pre-blocked polymer having only one labile hydroxyl group per polymer moiety. In such polymers, X would represent a blocking group such as an alkoxy group of one to four carbon atoms. The preferred blocking group is a methoxy group. For the preparation of homobifunctional and monofunctional polymer derivatives, see Buckmann et al., Makromol. Chem., 182(5), 1379-84 (1981). X can also represent an antibody or solid support covalently coupled to the polymer by methods known to those skilled in the art as illustrated in EP 295,073.

L is preferably -O- or -CH<sub>2</sub>-. When L is an amino acid or peptide residue, L preferably contains between 1 and 20 amino acids, and more preferably between 1 and 4 amino acids. The amino acids are preferably naturally occurring amino acids. The terminal amino group is positioned opposite the azlactone ring.

The unsaturated azlactone activated polyalkylene

10

15

20

25

30

oxides of Formula IA, in which R<sub>1</sub> is selected from and heterocyclic aromatic carbocyclic  $\alpha, \beta$ -unsaturated alkyl moieties are formed by reacting the aldehyde of Formula III in a reaction mixture containing acetic anhydride and the  $\alpha$ -acyl amino acid substituted polyalkylene oxide of Formula II, in which X, L and R are the same as described above with respect to Formula IA. The resulting azlactone is hydrolytically stable, yet readily with stronger nucleophiles ring-opening reaction. R1 is preferably an aromatic ring selected from benzene, naphthalene, pyrene, biphenyl, thiophene, furan, pyrrole, indole, chromane, coumarone The rings may be substituted or and thiazole rings. unsubstituted. Preferred substituents include haloalkyl, hydroxyl, alkoxy, acyloxy, carbethoxy and nitro moieties and combinations thereof.

The unsaturated azlactone activated polyalkylene oxides of Formula IA may also be formed by first reacting the  $\alpha$ -acyl amino acid substituted polyalkylene oxide of Formula II, with acetic anhydride to obtain the saturated azlactone substituted polyalkylene oxide of Formula IB in which  $R_4$  and  $R_5$  are both hydrogen. The resulting product represents an intermediate in the synthesis of the unsaturated azlactone activated polyalkylene oxides of Formula IA. The saturated azlactone can then be reacted with the aldehyde of Formula III to form the unsaturated azlactone-activated polyalkylene oxides of Formula IA, in which  $R_1$  is selected from carbocyclic and heterocyclic aromatic rings and  $\alpha,\beta$ -unsaturated alkyl moieties.

Acetic anhydride, when present, is utilized as the reaction solvent. Otherwise, the reaction is carried out in a non-hydroxylic solvent in which the reactants are soluble, such as toluene. A reaction temperature between about 75°C and about 110°C is suitable, and a temperature

10

15

20

25

30

between about 95°C and about 100°C is preferred. All materials must be essentially free of water. Scrupulous care must be taken not to contaminate the reaction mixture with water.

The polyalkylene oxides of Formula II are formed by In the first methods. method, of two one hydroxyl-terminated polyalkylene oxide is reacted with an isocyanate-substituted compound selected so that the resulting compound corresponds to an amino acid or peptide sequence coupled to a polyalkylene oxide via a Thus, ethyl isocyanatoacetate will urethane linkage. form a -O-CO-glycine ethyl ester terminated polyalkylene oxide, which can be converted to the carboxylic acid using well-known techniques. Ethyl 3-isocvanatopropionate will form a  $-0-c0-\beta$ -alanine ethyl ester terminated polyalkylene oxide. This reaction is carried out in a non-hydroxyl solvent in which the reactants are Again, the reaction mixture soluble, such as toluene. should not be contaminated with water. Reaction temperatures between 10°C and 50°C are suitable, and temperatures between 20°C and 30°C are preferred.

The ethyl isocyanoacetate product represents the polyalkylene oxide of Formula II in which L is -O-. The -O-CO-amino acid or -O-CO-peptide sequence terminated reaction product can be extended by coupling additional amino acids or peptide sequences to the reaction product by well-known reactions utilizing coupling reagents such as carbodiimides. (See Bodenszky, <u>Principles of Peptide Synthesis</u> (Springer-Verlag, New York, 1984)). Formula II requires that the terminal amino acid be glycine.

In the second method, a polyalkylene oxide carboxylic acid or acid chloride is reacted with an amino acid or peptide sequence. Polyalkylene oxide carboxylic acids and acid chlorides can be prepared by the method

10

15

20

25

30

disclosed by Buckmann et al., <u>Makromol Chem.</u>, <u>182(5)</u>, 1379-84 (1981), or by the method of U.S. Patent No. 5,122,614, the disclosure of which is hereby incorporated herein by reference thereto. This reaction is also carried out utilizing well-known techniques in a non-hydroxyl solvent such as toluene. When the carboxylic acid is utilized, the reaction should be mediated with a coupling reagent such as a carbodiimide. (Again, See Bodanszky, <u>Principles of Peptide Synthesis</u>.) Reaction temperatures between 4°C and 40°C are suitable, and temperatures between 10°C and 20°C are preferred. Once more, care should be taken not to contaminate the reaction mixture with water.

When the amino acid is glycine, the reaction product represents the polyalkylene oxide of Formula II in which L is -CH<sub>2</sub>-. Again, the amino acid or peptide sequence terminated reaction product can be extended by coupling additional amino acids or peptide sequences according to the method of Bodanszky, <u>Principles of Peptide Synthesis</u>, provided that the terminal amino acid is glycine.

The unsaturated azlactone activated polyalkylene oxides of Formula IA may also be formed by reacting the a-acyl amino acid terminated polyalkylene oxide of Formula IIA with acetic anhydride. X, L, R and  $R_1$  are the same as described above with respect to Formula IA and II.  $R_6$  is a moiety selected from hydroxyl, alkoxy and alkyl ester moieties.

The polyalkylene oxides of Formula IIA are also formed by the methods utilized in the preparation of the polyalkylene oxides of Formula II. However, instead of glycine, the terminal amino acid has a structure corresponding to Formula IV:

$$R_6$$
-CH- $R_1$   
 $H_2$ N-CH-COOH (IV)

in which  $R_1$  is the same as described above with respect to Formula IIA, and  $R_6$  is a hydroxyl, alkoxy or alkyl ester moiety.

As will be readily appreciated, Formula IV includes naturally occurring protein amino acids such as serine, threonine and the alkyl ester of aspartic acid.

The saturated azlactone activated polyalkylene oxides of Formula IB are formed by reacting the  $\alpha$ -acyl amino acid terminated polyalkylene oxide of Formula IIB with acetic anhydride. X, R and L are the same as described above with respect to Formula IA.  $R_4$  and  $R_5$  are independently selected from hydrogen, alkyl, aryl and alkylaryl moieties.

The polyalkylene oxides of Formula IIB are also formed by the methods utilized in the preparation of the polyalkylene oxides of Formula II. The terminal amino acid has a structure corresponding to Formula II:

$$H_2N$$
-C-COOH (V)

20

25

10

15

in which  $R_4$  and  $R_5$  are the same as described above with respect to Formula IIB.

As will be readily appreciated, when  $R_4$  and  $R_5$  are both hydrogen, the structure of Formula V represents glycine, which is thus a suitable terminal amino acid in this embodiment of the invention. Formula V also includes naturally occurring protein amino acids such as alanine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, thyroxine, tyrosine and valine.

30 The azlactone activated polyalkylene oxides are purified from low molecular weight materials by conventional methods. The azlactone can then be reacted with biologically active nucleophiles to form a

hydrolytically stable linkage between the polyalkylene

10

15

20

25

30

oxide and the biologically active nucleophile. The resulting product represents a biologically active conjugate of the nucleophile and the polyalkylene oxide.

The term "hydrolytically stable" means that the azlactones of the present invention, in aqueous solution, will not undergo substantial degradation at physiological pH and at temperatures up to 27°C. Degradation of less than 50% under these conditions over an eight hour time period is considered insubstantial.

The term "biologically active" is used with respect to the nucleophiles of the present invention consistently with the meaning commonly understood to those of ordinary skill in the art, which meaning is not limited to physiological or pharmacological activities of the nucleophiles in the therapeutic sense. For example, many physiologically active nucleotides such as enzymes, the polyalkylene oxide conjugates of which may not have therapeutic applications, are able to catalyze reactions in organic solvents. Likewise, regardless of the therapeutic uses for polyalkylene oxide conjugates of proteins such as concanavalin A, immunoglobulins, and the like, the polyalkylene oxide conjugates of these proteins are also useful as laboratory diagnostic tools.

The polyalkylene oxide conjugates of the biologically active nucleophiles of the present invention are biologically active and possess numerous therapeutic applications. Mammals in need thereof may be treated by administering a therapeutically effective amount of the biologically active polyalkylene oxide conjugates of the biologically active nucleophiles of the present invention.

Therefore, the biologically active nucleophiles of interest to the present invention include a variety of enzymes, including, but not limited to,

10

15

20

25

30

carbohydrate-specific enzymes, proteolytic enzymes, and the like. Enzymes of interest, for both biological applications in general and therapeutic applications in particular include the oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases disclosed by U.S. Patent No. 4,179,337, the disclosure of which is hereby incorporated herein by reference thereto. Without being limited to particular enzymes, examples of specific enzymes of interest include asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase and bilirubin oxidase. Carbohydrate-specific enzymes of interest include glucose oxidase, glucosidase, galactosidase, glucocerebrosidase, glucuronidase, etc.

The biologically active nucleophiles of the present invention also include proteins of general biological or therapeutic interest, including, but not limited to, hemoglobin and serum proteins such as Factor VIII, Factor IX, immunoglobulins, lectins, interleukins, interferons and colony stimulating factors, and ovalbumin and bovine Other proteins of albumin (BSA). serum biological or therapeutic interest include hormones such as insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones, somatomedins, erythropoietin, luteinizing hormone, hypothamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, and the like. Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.

Certain of the above proteins such as the interleukins, interferons and colony stimulating factors also exist in non-glycosilated form, usually the result of preparation by recombinant protein techniques. The

10

15

20

25

30

non-glycosilated versions are also among the biologically active nucleophiles of the present invention.

Other proteins of interest are allergen proteins disclosed by Derborg et al., <u>Crit. Rev. Therap. Drug Carrier Syst.</u>, <u>6</u>, 315-65 (1990) as having reduced allergenicity when conjugated with polyalkylene oxides, and consequently suitable for use as tolerance inducers. Among the allergins disclosed are ragweed Antigen E, honeybee venom, mite allergen, and the like.

Other biologically active nucleophiles the present invention include antibodies, antibody fragments, single chain antigens, nucleotides and oligonucleotides. The coupling of oligonucleotides to polyalkylene oxides disclosed by the above-cited U.S. Patent No. 4,904,582. Still other biologically active nucleophiles the scope of the invention included within therapeutically active nucleophilic compounds. compounds, nucleophilic active therapeutically chemotherapeutic molecules having appropriately reactive nucleophilic moieties are particularly preferred. example, anti-tumor agents, anti-infective agents, and in general, pharmaceutical chemicals the like, or. appropriate nucleophilic group, containing an included within the scope of the present invention.

One or more polyalkylene oxides can be attached covalently to the biologically active nucleophile by reacting the polyalkylene oxide azlactone with the nucleophile. The azlactone reacts with the nucleophile in a ring-opening reaction to form a linkage covalently bonding the nucleophiles to the polyalkylene oxide. When the nucleophile is a protein or polypeptide, conjugation occurs at the  $\epsilon$ -NH $_2$  moieties of lysines to form linkages containing stable glycine moieties.

For nucleophiles such as polypeptides, more than one

15

20

25

30

polyalkylene oxide conjugate per nucleophile is preferred. The degree of conjugation is limited only by the number of  $\epsilon\text{-NH}_2$  moieties of lysines. The optimum degree of conjugation can be readily determined for a particular nucleophile by one of ordinary skill in the art without undue experimentation. The degree of conjugation may be modified by varying the reaction stoichiometry using well-known techniques.

The reaction of azlactone activated polyalkylene oxides with the  $\epsilon$ -NH $_2$  moieties of polypeptide lysines is illustrated by the reaction sequence depicted below with the unsaturated azlactone activated polyalkylene oxide of Formula IB, in which R, L, X and R $_4$  and R $_5$  are the same as described above with respect to Formula IA and R $_3$  represents the balance of the polypeptide:

The unsaturated azlactone activated polyalkylene oxide of Formula IA reacts similarly.

The biologically active nucleophiles may be reacted directly with the azlactone activated polyalkylene oxides in an aqueous reaction medium. This reaction medium may also be buffered, depending upon the pH requirements of the nucleophile. The optimum pH for the reaction is generally between about 6.5 and about 8.0 and preferably about 7.4.

In all instances, the optimum reaction medium pH for the stability of particular nucleophiles and for reaction efficiency, and the buffer in which this can be achieved, is readily determined within the above ranges by those of ordinary skill in the art without undue experimentation.

10

15

20

25

30

For purposes of this application, the operativeness of the within reactions under mild conditions is defined as meaning that the preferred temperature range is between about 4 and about 37°C.

Those of ordinary skill in the art will understand that the reactions will run somewhat faster to completion at higher temperatures, with the proviso that the temperature of the reaction medium cannot exceed the temperature at which the nucleophile may denature or decompose. Furthermore, those of ordinary skill in the certain nucleophiles, will understand that art particularly polypeptides, will require reaction with the azlactone activated polyalkylene oxides at reduced temperatures to minimize loss of activity and/or to prevent denaturing. The reduced temperature required by particular polypeptides is preferably no lower than 4°C and in no event should this temperature be lower than O°C. The reaction will still take place, although longer reaction times may be necessary.

Usually, the nucleophile is reacted in aqueous solution with a quantity of the azlactone activated polyalkylene oxide in excess of the desired degree of conjugation. Following the reaction, the conjugated product is recovered and purified by diafiltration, column chromatography or the like.

In view of the foregoing, it can be readily appreciated that the azlactone activated polyalkylene oxides of the present invention possess the optimum balance of reactivity and hydrolytic stability so that polymer conjugates can be formed with biologically active nucleophiles with an insubstantial amount of hydrolytic degradation of the activated polyalkylene oxide. Thus, reaction yields are increased and process costs are reduced.

The following non-limiting examples illustrate certain aspects of the invention. All parts and percentages are by weight unless otherwise noted, and all temperatures are in degrees Celsius.

5

#### EXPERIMENTAL

## EXAMPLE 1

## Preparation Of m-PEG-\(\beta\)-Alanine

10

15

20

25

substituted poly(ethylene glycol β-alanine monomethyl ether) (m-PEG) is prepared for coupling with The m-PEG- $\beta$ -alanine-glycine to be prepared glycine. corresponds to the amino acid substituted polyalkylene oxide of Formula II in which X is methoxy, R is PEG and The m-PEG is  $\beta$ -alanine L is -O-CO-NH-CH<sub>2</sub>-CH<sub>2</sub>-. substituted by adding 100 g (20 mmol.) m-PEG-OH (Union Carbide) to 700 mL of toluene. The m-PEG-OH has a number average molecular weight of 5,000 daltons. The solution is refluxed for four hours, under nitrogen, in a flask equipped with a Dean-Stark trap. During this time, a total of 200 mL of solvent is removed from the trap. The reaction mixture is then cooled to 40°C, followed by the ethyl 3-isocyanatopropionate addition of 50 mmol.) and Sn(II) octoate (0.3 g) (Aldrich Chemical The reaction mixture is maintained at 40°C for 16 hours. Removal of solvent and recrystallization from one liter of 2-propanol gave 93 g (93 percent) of the m-PEG- $\beta$ -alanine ethyl ester. The <sup>1</sup>H and <sup>13</sup>C NMR spectra are consistent with the structure.

30

The m-PEG- $\beta$ -alanine ethyl ester (77 g, 15 mmol.) is dissolved in 500 mL of water and to this solution is added 5 g (125 mmol.) of sodium hydroxide. The pH of the solution is 11.75. The solution is allowed to stir at room temperature for 2.5 hours and then acidified with

15

20

25

30

HCl to pH 2-3. After dissolving 125 g NaCl, the reaction mixture is extracted with two 250 mL portions of methylene chloride. The extract is dried over MgSO<sub>4</sub>, followed by solvent evaporation, and recrystallization from 750 mL 2-propanol, wherein 73 g (95 percent) m-PEG- $\beta$ -alanine is obtained. Both <sup>1</sup>H and <sup>13</sup>C NMR spectra showed the disappearance of the ethyl group of the ester.

#### EXAMPLE 2

# 10 Preparation Of m-PEG-β-Alanine-Glycine

The m-PEG- $\beta$ -alanine of Example 1 (5.1 g, 1 mmol.) is dissolved in 50 mL of pH 5.5 acetate buffer, and to the added 21 mg (1.1 mmol.) are solution 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide chloride (EDC) and 280 mg (2.0 mmol.) of glycine ethyl ester hydrochloride (Aldrich Chemical Co.). The reaction mixture is stirred for two hours and the pH is maintained at 5.5 by the addition of 0.1 N HCl. The product is isolated by extraction with methylene chloride, followed solvent evaporation MgSO4, drying over recrystallization from 2-propanol as in the case of m-PEG- $\beta$ -alanine of Example I. The ester group is removed by hydrolysis with 0.25 M NaOH as in Example I for <sup>13</sup>C NMR The <sup>1</sup>H and spectra m-PEG- $\beta$ -alanine. consistent with the structure.

## EXAMPLE 3

# Preparation Of An Unsaturated Azlactone

The m-PEG- $\beta$ -alanine-glycine of Example 2 (2.6 g, 0.50 mmol.), benzaldehyde (58 mg, 0.55 mmol.), sodium acetate (45 mg, 0.55 mmol.), and acetic anhydride (168 mg, 1.65 mmol.) are heated in a water bath at 80°C for thirty minutes. The reaction mixture is poured into 20 mL ice water and extracted with methylene chloride,

15

20

25

30

dried over  $MgSO_4$  and concentrated according to the work-up procedure of Example I. The pure product is then precipitated with ether and dried under high vacuum. The product is characterized by IR and NMR, and the spectral data are consistent with the structure of the unsaturated azlactone activated polyalkylene oxide of Formula IA in which X is methoxy, R is PEG, L is -O-CO-NH-CH<sub>2</sub>-CH<sub>2</sub>- and R<sub>1</sub> is a phenyl moiety.

#### 10 EXAMPLE 4

# Preparation of m-PEG-Glycine With A Urethane Linkage

m-PEG substituted was prepared, glycine corresponding to the amino acid substituted polyalkylene oxide of Formula II in which X is methoxy, R is PEG and The m-PEG was glycine substituted by first L is -0-. drying 50 g (10 mmol.) m-PEG-OH (Union Carbide) as in Example 1. The 5,000 dalton number average molecular weight polymer was used again. The dried toluene solution is cooled to 40°C, followed by the addition of ethyl isocyanatoacetate (1.7 g, 15 mmol.) to obtain m-PEG-glycine ethyl ester, which is hydrolyzed by 0.25 N sodium hydroxide to m-PEG-glycine, and then worked up and isolated following the procedures of Example 1. product is characterized by IR and NMR, and the spectral data are consistent with the structure.

#### EXAMPLE 5

## Preparation Of A Saturated Azlactone

The m-PEG-glycine of Example 4 (5.1 g, 1.0 mmol.) is added to 50 mL of acetic anhydride and heated in a water bath at 100°C for ten minutes. The reaction mixture is poured into an ice water bath and the pure product is isolated and worked up as described in Example 3. The product is characterized by IR and NMR, and the spectral

data are consistent with the structure of the saturated azlactone activated polyalkylene oxide of Formula IB in which X is methoxy, R is PEG, L is -0- and  $R_4$  and  $R_5$  are both hydrogen.

5

10

15

20

25

30

#### EXAMPLE 6

## Preparation Of An Unsaturated Azlactone

The saturated azlactone of Example 5 (5.1 g, 1.0 mmol.) and benzaldehyde (120 mg, 1.1 mmol.) are added to 50 mL of methylene chloride and heated in a water bath at  $35^{\circ}$ C for 60 minutes. The reaction mixture is quenched and the unsaturated azlactone is isolated and worked up as in Example 3. The IR and NMR spectra are consistent with the structure of the unsaturated azlactone activated polyalkylene oxide of Formula IA in which X is methoxy, R is PEG, L is -0- and R<sub>1</sub> is a phenyl moiety.

#### EXAMPLE 7

# Conjugation Of An Unsaturated Azlactone With Hemoglobin

The unsaturated azlactone activated polyalkylene oxide of Example 6 is conjugated with bovine hemoglobin by first preparing a 10 mL solution of pH 7.8 phosphate buffer by dissolving 0.1380 g NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O and 0.2338 g NaCl in 7.0 mL deionized water. The pH of this solution is then adjusted to 7.8 with 1.0 N NaOH and diluted to 10 mL with deionized water. A of isolated bovine hemoglobin 4.0 mL sample (10.9 percent, 7.02 x  $10^{-3}$  mmol.) is measured into a 50 mL jacketed beaker chilled to 4°C by means of a refrigerated recirculating bath. A thermometer and pH electrode were placed in the hemoglobin solution, which is stirred magnetically. The pH of the hemoglobin is adjusted to 7.8 with 1.0 N NaOH or 1.0 N HCl as necessary.

To this is added 0.65 g of the unsaturated azlactone

10

20

25

30

of Example 6 (0.13 mmol.) followed by 4.0 mL of the pH 7.8 phosphate buffer prepared above. The mixture is allowed to stir at 4°C for one hour while maintaining pH 7.8 with dropwise additions of 1.0 N NaOH or 1.0 N HCl. After one hour of reaction time, 42 mg (0.24 mmol.) of cysteine HCl is added, followed by 9.5 mg (0.13 mmol.) of The pH is adjusted up to 7.8 using 1.0 N NaOH, and the mixture is allowed to stir for 15 minutes. product is stored in a 4°C refrigerator. The final hemoglobin concentration of the product was about Capillary zone electrophoresis results 5 percent. indicate that PEG conjugation of the hemoglobin was effected by this procedure.

#### 15 EXAMPLE 8

#### Preparation Of m-PEG-β-Alanine-Alanine

m-PEG- $\beta$ -alanine-alanine is prepared following the procedure utilized to prepare the m-PEG- $\beta$ -alanine-glycine of Example 2, substituting .307 mg (2.0 mmol.) of alanine ethyl ester hydrochloride (Aldrich Chemical Co.) for the glycine ethyl ester hydrochloride. Following removal of the ester group, the  $^1H$  and  $^{13}C$  NMR spectra are consistent with the structure of the amino acid substituted polyalkylene oxide of Formula IIB in which X is methoxy, R is PEG, L is -O-CO-NH-CH<sub>2</sub>-CH<sub>2</sub>-, R<sub>4</sub> is methyl and R<sub>5</sub> is hydrogen.

### EXAMPLE 9

# Preparation Of A Saturated Azlactone

The m-PEG- $\beta$ -alanine-alanine of Example 8 (2.6 g, 0.5 mmol.) is added to 50 mL of acetic anhydride and heated in a water bath at 100°C for ten minutes. The reaction mixture is poured into 200 mL ice water and stirred for twenty minutes. The product is isolated by

15

extraction with two 100 mL portions of methylene chloride. The extract is dried over  $MgSO_4$ , concentrated, precipitated with ether, and dried under high vacuum as in the procedure of Example 3. The product is characterized by IR and NMR, and the spectral data are consistent with the structure of the saturated azlactone activated polyalkylene oxide of Formula IB in which X is methoxy, R is PEG, L is  $-0-CO-NH-CH_2-CH_2-$ ,  $R_4$  is methyl and  $R_5$  is hydrogen.

As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

#### WHAT IS CLAIMED IS:

- A water-soluble, hydrolytically-stable,
   azlactone-activated, polyalkylene oxide.
- 2. The azlactone-activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.
- 3. The azlactone-activated polyalkylene oxide of claim 2, wherein said polyalkylene oxide comprises polyethylene glycol.
- 4. The azlactone-activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide has a number average molecular weight between about 600 and about 100,000 daltons.
- 5. The azlactone-activated polyalkylene oxide of claim 4, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.
- 6. The azlactone-activated polyalkylene oxide of claim 5, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.
- 7. The azlactone-activated polyalkylene oxide of claim 1, comprising an unsaturated azlactone activated polyalkylene oxide having a structure represented by:


wherein R is a water-soluble polyalkylene oxide:

L is selected from the group consisting of -0-,  $-CH_2-$  and amino acid and peptide residues;

 $R_{\rm l}$  is a moiety selected from the group consisting of hydrogen, alkyl and cycloalkyl moieties, carbocyclic and heterocyclic aromatic rings and  $\alpha,\beta$ -unsaturated alkyl moieties; and

X is a terminal moiety of said polyalkylene oxide.

- 8. The unsaturated azlactone-activated polyalkylene oxide of claim 7, wherein  $R_i$  is an aromatic ring selected from the group consisting of substituted and unsubstituted benzene, napthalene, pyrene, biphenyl, thiophene, furan, pyrrole, indole, chromane, coumarone and thiazole rings.
- 9. The unsaturated azlactone-activated polyalkylene oxide of claim 7, wherein X is a moiety selected from the group consisting of alkoxy moieties containing up to four carbon atoms.
- 10. The unsaturated azlactone-activated polyalkylene oxide of claim 9, wherein X is a methoxy moiety.
- 11. The azlactone-activated polyalkylene oxide of claim 1, comprising a saturated azlactone activated polyalkylene oxide having a structure represented by:



wherein R is a water-soluble polyalkylene
oxide;

L is selected from the group consisting of -O-, -CH<sub>2</sub>- and amino acid and peptide residues;

 $R_{\!\scriptscriptstyle 4}$  and  $R_{\!\scriptscriptstyle 5}$  are moieties independently selected from the group consisting of hydrogen, alkyl, aryl and

alkylaryl moieties; and

X is a terminal moiety of said polyalkylene oxide.

- 12. The saturated azlactone activated polyalkylene oxide of claim 11, wherein at least one of  $R_4$  and  $R_5$  is a moiety selected from the group consisting of alkyl, aryl and alkylaryl moieties.
- 13. The saturated azlactone activated polyalkylene oxide of claim 11, wherein both  $R_4$  and  $R_5$  are hydrogen.
- 14. The saturated azlactone activated polyalkylene oxide of claim 11, wherein X is a moiety selected from the group consisting of alkoxy moieties containing up to four carbon atoms.
- 15. A polyalkylene oxide conjugate comprising: a nucleophile having biological activity; and
- at least one water-soluble polyalkylene oxide covalently bonded thereto by a hydrolytically stable linkage formed by reacting said nucleophile with an azlactone-activated polyalkylene oxide.
- 16. The polyalkylene oxide conjugate of claim 15, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.
- 17. The polyalkylene oxide conjugate of claim 15, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.
- 18. The polyalkylene oxide conjugate of claim 17, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.
- 19. The polyalkylene oxide conjugate of claim 15, wherein said azlactone activated polyalkylene oxide

comprises an unsaturated azlactone ring.

- 20. The polyalkylene oxide conjugate of claim 15, wherein said azlactone activated polyalkylene oxide comprises a saturated azlactone ring.
- 21. A method of forming a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded thereto, said method comprising the steps of:

contacting a biologically active nucleophile with one or more azlactone activated polyalkylene oxides, so that a biologically active conjugate of said biologically active nucleophile and said polyalkylene oxides is formed; and recovering said biologically active conjugate.

- 22. The method of claim 21, wherein said azlactone activated polyalkylene oxides comprise unsaturated azlactone rings.
- 23. The method of claim 21, wherein said azlactone activated polyalkylene oxides comprise saturated azlactone rings.
- 24. A method of treatment comprising administering to a mammal in need thereof a therapeutically effective amount of the polyalkylene oxide conjugate of claim 15.
- 25. A process for the preparation of an unsaturated azlactone activated polyalkylene oxide, said process comprising the steps of:

providing an  $\alpha$ -acyl amino acid substituted polyalkylene oxide having a structure represented by:

X-R-L-CO-NH-CH2-COOH

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -0-,  $-CH_2-$  and amino acid and peptide residues; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted

polyalkylene oxide with acetic anhydride and an aldehyde having a structure represented by:

wherein  $R_1$  is a moiety selected from the group consisting of carbocyclic and heterocyclic aromatic rings and  $\alpha,\beta$ -unsaturated alkyl moieties, so that an unsaturated azlactone activated polyalkylene oxide is formed having a structure corresponding to:

26. The process of claim 25, wherein said reacting step comprises the steps of:

contacting said amino acid substituted polyalkylene oxide with acetic anhydride, so that a saturated azlactone substituted polyalkylene oxide is formed having a structure corresponding to:

and reacting said saturated azlactone substituted polyalkylene oxide with said aldehyde, so that said unsaturated azlactone activated polyalkylene oxide is formed.

- 27. The process of claim 25, wherein said reacting step comprises reacting said amino acid substituted polyalkylene oxide in a reaction mixture comprising both acetic anhydride and said aldehyde.
- 28. A process for the preparation of an unsaturated azlactone activated polyalkylene oxide, said process comprising the steps of:

providing an  $\alpha$ -acyl amino acid substituted

polyalkylene oxide having a structure represented by:

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -O-, -CH<sub>2</sub>- and amino acid and peptide residues;  $R_1$  is a moiety selected from the group consisting of hydrogen, alkyl and cycloalkyl moieties, carbocyclic and heterocyclic aromatic rings and  $\alpha,\beta$ -unsaturated alkyl moieties;  $R_6$  is a moiety selected from the group consisting of hydroxyl, alkoxy and alkyl ester moieties; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted polyalkylene oxide with acetic anhydride so that an azlactone activated polyalkylene oxide is formed having a structure:


29. A process for the preparation of a saturated azlactone activated polyalkylene oxide, said process comprising the steps of:

providing an  $\alpha$ -acyl amino acid substituted polyalkylene oxide having a structure represented by:

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -0-,  $-CH_2-$  and amino acid and peptide residues;  $R_4$  and  $R_5$  are moieties independently selected from the group consisting of hydrogen, alkyl, aryl and alkylaryl moieties; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted

polyalkylene oxide with acetic anhydride so that a saturated azlactone activated polyalkylene oxide is formed having a structure corresponding to:



30. The process of claim 29, wherein at least one of  $R_4$  and  $R_5$  is a moiety selected from the group consisting of alkyl, aryl and alkylaryl moieties.

#### AMENDED CLAIMS

received by the International Bureau on 14 June 1994 (14.06.94); original claims 4,7,9,11 and 14 cancelled; original claims 1,3,5,8,10,12 and 13 amended; remaining claims unchanged (7 pages)]

1. A water-soluble, hydrolytically-stable, azlactone-activated, polyalkylene oxide, comprising a structure represented by:

or

wherein R represents the non-terminal portion of a water-soluble polyalkylene oxide having a number average molecular weight between about 600 and about 100,000 daltons;

L is selected from the group consisting of -0- and  $-CH_2-;$ 

 $R_1$  is a moiety selected from the group consisting of hydrogen, alkyl and cycloalkyl moieties, carbocyclic and heterocyclic aromatic rings and  $\alpha, \beta$ -unsaturated alkyl moieties;

 $R_4$  and  $R_5$  are moieties independently selected from the group consisting of hydrogen, alkyl, aryl and alkylaryl moieties; and

X is a terminal moiety of said polyalkylene oxide selected from the group consisting of alkoxy moieties containing up to four carbon atoms.

- 2. The azlactone-activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.
- 3. The azlactone-activated polyalkylene oxide of claim 2, wherein said polyalkylene oxide is polyethylene glycol.
  - 4. Cancelled.

WO 94/18247

- 5. The azlactone activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.
- 6. The azlactone-activated polyalkylene oxide of claim 5, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.
  - 7. Cancelled.
- 8. The unsaturated azlactone-activated polyalkylene oxide of claim 1, wherein  $R_1$  is an aromatic ring selected from the group consisting of substituted and unsubstituted benzene, napthalene, pyrene, biphenyl, thiophene, furan, pyrrole, indole, chromane, coumarone and thiazole rings.
  - 9. Cancelled.
- 10. The unsaturated azlactone-activated polyalkylene oxide of claim 1, wherein X is a methoxy moiety.

- 11. Cancelled.
- 12. The saturated azlactone activated polyalkylene oxide of claim 1, wherein at least one of  $R_4$  and  $R_5$  is a moiety selected from the group consisting of alkyl, aryl and alkylaryl moieties.
- 13. The saturated azlactone activated polyalkylene oxide of claim 1, wherein both  $R_4$  and  $R_5$  are hydrogen.
  - ·14. Cancelled.
- 15. A polyalkylene oxide conjugate comprising:

  a nucleophile having biological activity;
  and

at least one water-soluble polyalkylene oxide covalently bonded thereto by a hydrolytically stable linkage formed by reacting said nucleophile with an azlactone-activated polyalkylene oxide.

- 16. The polyalkylene oxide conjugate of claim 15, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.
- 17. The polyalkylene oxide conjugate of claim 15, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.
- 18. The polyalkylene oxide conjugate of claim 17, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.
- 19. The polyalkylene oxide conjugate of claim 15, wherein said azlactone activated polyalkylene oxide

WO 94/18247

comprises an unsaturated azlactone ring.

- 20. The polyalkylene oxide conjugate of claim 15, wherein said azlactone activated polyalkylene oxide comprises a saturated azlactone ring.
- 21. A method of forming a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded thereto, said method comprising the steps of:

contacting a biologically active nucleophile with one or more azlactone activated polyalkylene oxides, so that a biologically active conjugate of said biologically active nucleophile and said polyalkylene oxides is formed; and recovering said biologically active conjugate.

- 22. The method of claim 21, wherein said azlactone activated polyalkylene oxides comprise unsaturated azlactone rings.
- 23. The method of claim 21, wherein said azlactone activated polyalkylene oxides comprise saturated azlactone rings.
- 24. A method of treatment comprising administering to a mammal in need thereof a therapeutically effective amount of the polyalkylene oxide conjugate of claim 15.
- 25. A process for the preparation of an unsaturated azlactone activated polyalkylene oxide, said process comprising the steps of:

 $\label{eq:continuous} \text{providing an $\alpha$-acyl amino acid substituted} \\ \text{polyalkylene oxide having a structure represented by:} \\$ 

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -O-,  $-CH_2-$  and amino acid and peptide residues; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted

polyalkylene oxide with acetic anhydride and an aldehyde having a structure represented by:

 $R_1-C=0$ 

wherein  $R_1$  is a moiety selected from the group consisting of carbocyclic and heterocyclic aromatic rings and  $\alpha, \beta$ -unsaturated alkyl moieties, so that an unsaturated azlactone activated polyalkylene oxide is formed having a structure corresponding to:

CHR

N C

X-R-L-

0

26. The process of claim 25, wherein said reacting step comprises the steps of:

contacting said amino acid substituted polyalkylene oxide with acetic anhydride, so that a saturated azlactone substituted polyalkylene oxide is formed having a structure corresponding to:

N CH<sub>2</sub>

X-R-L-

0

0

and reacting said saturated azlactone substituted polyalkylene oxide with said aldehyde, so that said unsaturated azlactone activated polyalkylene oxide is formed.

- 27. The process of claim 25, wherein said reacting step comprises reacting said amino acid substituted polyalkylene oxide in a reaction mixture comprising both acetic anhydride and said aldehyde.
- 28. A process for the preparation of an unsaturated azlactone activated polyalkylene oxide, said process comprising the steps of:

providing an  $\alpha$ -acyl amino acid substituted

WO 94/18247

polyalkylene oxide having a structure represented by:  $R_s$ -CH- $R_t$ 

#### X-R-L-CO-NH-CH-COOH

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -O-, -CH<sub>2</sub>- and amino acid and peptide residues;  $R_1$  is a moiety selected from the group consisting of hydrogen, alkyl and cycloalkyl moieties, carbocyclic and heterocyclic aromatic rings and  $\alpha,\beta$ -unsaturated alkyl moieties;  $R_6$  is a moiety selected from the group consisting of hydroxyl, alkoxy and alkyl ester moieties; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted polyalkylene oxide with acetic anhydride so that an azlactone activated polyalkylene oxide is formed having a structure:

N CHR<sub>1</sub>

X-R-L-

C

O

29. A process for the preparation of a saturated azlactone activated polyalkylene oxide, said process comprising the steps of:

providing an  $\alpha$ -acyl amino acid substituted polyalkylene oxide having a structure represented by:

 $R_4$ 

X-R-L-CO-NH-C-COOH

 $R_5$ 

wherein R is a water-soluble polyalkylene oxide; L is selected from the group consisting of -0-,  $-CH_2-$  and amino acid and peptide residues;  $R_4$  and  $R_5$  are moieties independently selected from the group consisting of hydrogen, alkyl, aryl and alkylaryl moieties; and X is a terminal moiety of said polyalkylene oxide; and

reacting said amino acid substituted

polyalkylene oxide with acetic anhydride so that a saturated azlactone activated polyalkylene oxide is formed having a structure corresponding to:

 $R_4$ 

0

N

 $R_5$  (IB)

X-R-L

0

30. The process of claim 29, wherein at least one of  $R_4$  and  $R_5$  is a moiety selected from the group consisting of alkyl, aryl and alkylaryl moieties.

# STATEMENT UNDER ARTICLE 19

Claim 1 has been amended to recite specific azlactone-activated polyalkylene oxides having molecular weights ranging from 600 to 100,000 daltons. Claims 5, 8, 10, 12 and 13 have been amended to change their respective dependency in view of cancelled claims.

#### REMARKS

In the International Search Report, the Authorized Officer indicated that claims 1-6 and 11-13 lack novelty or cannot be considered to involve an inventive step in view of U.S. Patent Nos. 4,485,236 and 5,157,108. Applicant respectfully submits that the claims presented herein are not anticipated by these references.

The present invention includes specific azlactone-activated polyalkylene oxides having molecular weights from 600 to 100,000. The hydrolytically-stable activated polymers resist hydroxyl attack under the pH conditions required for conjugation reactions. Reactions carried out in aqueous systems are high yielding because aminolysis predominates over hydrolysis. Methods of preparing the activated polymer as well as conjugates including the activated polymer are also included.

U.S. Patent No. 4,485,236 discloses azlactone compounds which are useful in the preparation of polyamide resins. U.S. Patent No. 5,157,108 discloses azlactone crosslinking compounds. Azlactone-activated polyalkylene oxides having molecular weights from 600 to 100,000 are not disclosed.

The amended claims and remarks presented herein are believed to render observations of the Authorized Officer concerning claims 1-6 and 11-13 moot. Reconsideration of the claims is respectfully requested.

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/01139

A. CLASSIFICATION OF SUBJECT MATTER						
IPC(5) :CO8F 8/48; CO7D 413/12 US CL :525/404; 548/227, 228 According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SEARCHED  Minimum documentation searched (classification system followed by classification symbols)						
U.S. : 525/404; 548/227, 228						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)						
C. DOCUMENTS CONSIDERED TO BE RELEVANT						
Category* Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.				
X US, A, 4,485,236 (RASMUSSEN 1984, see entire document.	I ET AL.) 27 NOVEMBER	1-6,11-13				
X US, A, 5,157,108 (KREPSKI ET see entire document.	US, A, 5,157,108 (KREPSKI ET AL.) 20 OCTOBER 1992, 1-6, 11-13 see entire document.					
Further documents are listed in the continuation of Box	C. See patent family annex.					
Special categories of cited documents:  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention						
to be part of particular relevance	"X" document of particular relevance; th	e claimed invention cannot be				
"E" earlier document published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other	considered novel or cannot be conside when the document is taken alone	red to involve an inventive step				
special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance; the considered to involve an inventive combined with one or more other such	step when the document is h documents, such combination				
"P" document published prior to the international filing date but later than	being obvious to a person skilled in the "&" document member of the same patent					
Date of the actual completion of the international search	Date of mailing of the international sea	arch report				
14 MARCH 1994 7 5 APR 1994						
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT FREDERICK KRASS  Authorized officer FREDERICK KRASS						
Washington, D.C. 20231 Facsimile No. (703) 305-3230	Telephone No. (703) 308-2351					